company background image
A065650 logo

Hyper KOSDAQ:A065650 Stock Report

Last Price

₩1.35k

Market Cap

₩113.2b

7D

-9.2%

1Y

-19.3%

Updated

20 Jun, 2024

Data

Company Financials

Hyper Corporation Inc.

KOSDAQ:A065650 Stock Report

Market Cap: ₩113.2b

A065650 Stock Overview

A clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics.

A065650 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Hyper Corporation Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hyper
Historical stock prices
Current Share Price₩1,348.00
52 Week High₩2,565.00
52 Week Low₩920.00
Beta0
11 Month Change-8.49%
3 Month Change-4.74%
1 Year Change-19.33%
33 Year Change-58.65%
5 Year Change-72.74%
Change since IPO-55.07%

Recent News & Updates

Recent updates

Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?

Mar 15
Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?

Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its Debt

Nov 29
Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its Debt

Shareholder Returns

A065650KR ElectronicKR Market
7D-9.2%1.0%2.0%
1Y-19.3%-20.7%6.7%

Return vs Industry: A065650 exceeded the KR Electronic industry which returned -20.7% over the past year.

Return vs Market: A065650 underperformed the KR Market which returned 6.7% over the past year.

Price Volatility

Is A065650's price volatile compared to industry and market?
A065650 volatility
A065650 Average Weekly Movement5.5%
Electronic Industry Average Movement5.6%
Market Average Movement5.0%
10% most volatile stocks in KR Market11.3%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A065650 has not had significant price volatility in the past 3 months.

Volatility Over Time: A065650's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aHyun-Sang Mukwww.hyper-corp.com

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents.

Hyper Corporation Inc. Fundamentals Summary

How do Hyper's earnings and revenue compare to its market cap?
A065650 fundamental statistics
Market cap₩113.18b
Earnings (TTM)-₩3.52b
Revenue (TTM)₩31.41b

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A065650 income statement (TTM)
Revenue₩31.41b
Cost of Revenue₩27.16b
Gross Profit₩4.25b
Other Expenses₩7.78b
Earnings-₩3.52b

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A065650 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.